Psychiatric Digital Biomarkers Market Report: Market Size & Forecast 2026

The psychiatric digital biomarkers market encompasses digital technologies that quantify behavioral, cognitive, and physiological signals relevant to psychiatric disorders such as depression, schizophrenia, bipolar disorder, and anxiety. These tools—including passive smartphone sensing, wearable biosensors, speech-pattern analysis, and digital cognitive testing—are increasingly being integrated into clinical trials, routine psychiatric care, and remote patient monitoring platforms. The market has grown from an estimated $631–812 million in 2024–2025 to approximately $942 million in 2026, marking the beginning of a sustained multi-year expansion.

• •Market valued at approximately $0.941 billion in 2026; prior-year estimates range from $631 million to $812 million
• •Projected to reach $2.3 billion by 2030–2031 at CAGR estimates between 19% and 25% across major market-research reports
• •Applications span clinical diagnostics, drug-development trial endpoints, remote monitoring, and personalized treatment planning

Escalating global prevalence of mental health disorders and growing unmet need for objective, quantifiable psychiatric assessment tools are the primary demand-side drivers. Advances in machine learning and artificial intelligence have dramatically improved the ability to interpret complex behavioral and physiological data streams, making digital biomarkers clinically actionable. Additionally, regulatory agencies are increasingly accepting digital endpoints in clinical trials, lowering barriers to adoption for pharmaceutical and biotechnology sponsors.

• •Global mental health burden and demand for objective, non-subjective psychiatric measurement tools
• •Advancing AI/ML capabilities enabling real-time analysis of voice, movement, and interaction patterns
• •Regulatory acceptance of digital endpoints in clinical trials accelerating pharmaceutical and biotech investment

The market is commonly segmented by biomarker type—including behavioral, cognitive, voice-based, and physiological biometric biomarkers—and by application across clinical diagnostics, drug development, and remote monitoring. North America dominates the market, reflecting its advanced healthcare infrastructure, significant mental health spending, and concentrated biopharmaceutical research activity. Europe and the Asia-Pacific region represent the next-largest markets, with Asia-Pacific expected to post the fastest relative growth rate over the forecast horizon due to expanding digital health adoption and rising healthcare investment.

• •North America leads regional market share, supported by mature healthcare systems and strong biopharma R&D presence
• •Asia-Pacific projected as the fastest-growing regional market due to digital health infrastructure expansion
• •Segments include behavioral, cognitive, speech/voice, and physiological biomarker categories across clinical and drug-development use cases

Who are the notable companies in the industry?

I can't complete this rewrite as specified, the research text provided does not mention Mindstrong, Akili Interactive, or Woebot Health by name, nor does it describe any specific company's products or positioning. Adding factual descriptors for those three firms "drawn only from the research text" isn't possible because the text contains zero information about them. What I **can** do from the research is describe the types of players active in the market using only the general characterizations found in the text (e.g., integrated producers developing hardware/software/analytics end-to-end, specialty providers focusing on narrow biomarker modalities, routes such as mobile-sensor data collection, cloud-based ML analytics, NLP for voice biomarkers, wearable integration). If you'd like me to produce a rewritten Competitive Landscape section that is faithful to the research text and mentions the three companies with descriptors based on that text, that would require adding information not present in the source material, which I shouldn't do

• •Moderately fragmented structure with both integrated end-to-end platform providers and narrow specialty biomarker companies
• •Technology routes include passive mobile sensing, wearable biometrics, voice/speech analytics, and digital cognitive testing platforms
• •Competitive positioning is increasingly determined by clinical trial partnerships, regulatory clearances, and the breadth of validated psychiatric indications

What are the recent trends and outlook?

Convergence of digital biomarkers with precision-psychiatry initiatives is expected to deepen over the forecast period, enabling more individualized treatment selection and dosing. The adoption of remote and decentralized clinical trial designs—accelerated by recent global healthcare delivery shifts—is further embedding digital biomarkers into mainstream pharmaceutical development pipelines. Ongoing investment in data standardization, interoperability frameworks, and prospective clinical validation studies will be critical to sustaining the market's double-digit growth trajectory.

• •Precision-psychiatry and personalized-treatment initiatives driving deeper integration of digital biomarker data into care pathways
• •Decentralized and remote clinical trial growth expanding the addressable market for digital biomarker endpoints
• •Data-standardization and interoperability efforts expected to unlock greater cross-platform adoption and regulatory acceptance